Navigation Links
WRAIR investigators pioneering work on an exciting new class of antimalarial compounds
Date:3/26/2008

March 26, 2008 Silver Spring, MD: Artemisinins in Malaria Therapy, written by WRAIR researchers Dr. Qugui Li, Dr. Wilbur K. Milhous, and Dr. (COL) Peter J. Weina (Division of Experimental Therapeutics at the WRAIR, Silver Spring, MD) provides a fascinating overview of the historical use and recent developments in the treatment of one of the oldest and still one of the most prevalent scourges of mankind malaria.

WRAIR, initially known as the Army Medical School, was founded in 1893 by then U.S. Army Surgeon General George Sternberg. In 1900 General Sternberg sent the newly appointed U.S. Army Yellow Fever Commission to Cuba headed by Major Walter Reed. Major Reed and his team became the first to confirm the theory that yellow fever was transmitted by a mosquito vector. Since this historic discovery, WRAIRs many contributions to mankind in its 100 plus year history includes the discovery of the etiology and treatment of many of mankinds leading killers.

More than half of the routine vaccines given to service members were co-developed by the military. Development of other licensed vaccines was supervised by investigators who began their careers at military research centers (e.g. yellow fever vaccine by former Army Surgeon General William Gorgas, mumps, measles, and varicella vaccines by Maurice Hilleman, and oral polio vaccine by Albert Sabin). Vaccines currently in advanced development stages include new adenovirus vaccines, and vaccines for malaria, dengue, and hepatitis E.

The history of using artemisinins for malarial like conditions dates back more than 2000 years to when it was a part of the herbal arsenal utilized in Traditional Chinese Medicine as a treatment for malarial like conditions. Artemisinins are derived from the sweet wormwood plant Artemisia annua which not only grows in China but also just down the road from WRAIR along the Potomac River. Revival of the use of artemisinins in the era of modern medicine began in China in the 1970s with the first purified crystalline artemisinins produced in Shandon Province in 1972.

Although lead author Dr. Qigui Li received his MD and pharmacology degrees in China in the early 1980s, he did not become aware of artemisinins until the late 1980s, while a Post-doctoral Fellow at the Free University of Berlin, Germany. Dr. Li stated that the Chinese had first published their findings in the Chinese Medical Journal in 1979, but when the WHO approached Chinese scientists for samples of the plant so they could conduct their own assays they were rebuffed. In retrospect, we can appreciate that this was just after the Nixon era, Mao Tse-tung was still in power, and the Chinese were very skeptical about sharing information for fear it would be utilized by the commercial pharmaceutical companies in the West for monetary gain. Since joining the WRAIR team in 1991, Dr. Li has performed or supervised the majority of the pharmacodynamics and pharmacokinetics on all of the artemisinin derivatives.

In December of 2005, the World Health Organization stated, for the first time, artemisinins are the first line of therapy for most cases of malarial illnesses. Artemisinins are also being investigated as antiviral and anticancer agents.


'/>"/>

Contact: Mike Fiedler
michael.fiedler@amedd.army.mil
301-319-9626
Walter Reed Army Institute of Research
Source:Eurekalert  

Related medicine news :

1. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
2. LCA Hails International Investigators Studying Lung Cancer
3. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
4. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
5. PSI Brings its Pioneering Efforts to a Close
6. American Academy of Ophthalmology Mourns Loss of Judah Folkman, MD, Pioneering Researcher
7. Boston IVF is First in Northeast to Offer Pioneering Test of Womens Biological Clock
8. Reproductive Medicine & Fertility Center is First in Southwest to Offer Pioneering Test of a Womens Biological Clock
9. Nosespray vaccine using aloe vera has exciting potential, researcher says
10. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
11. 3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
WRAIR investigators pioneering work on an exciting new class of antimalarial compounds
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: